Clinical Trial Update: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial evaluated the safety and tolerability of sub-retinal transplantation of human embryonic stem cell–derived retinal pigment epithelium (hESC-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• hESC-RPE sub-retinal transplant (human embryonic stem cell-derived retinal pigment epithelium cells)

Snippet

Sponsor: Astellas Institute for Regenerative Medicine | Conditions: Stargardt's Macular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED